8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Precursor T-cell lymphoblastic lymphomas (T-LBL) are rare aggressive hematological malignancies that mainly develop in children. As in other cancers, the loss of cell cycle control plays a prominent role in the pathogenesis in these malignancies that is primarily attributed to loss of CDKN2A (encoding protein p16INK4A). However, the impact of the deregulation of other genes such as CDKN1C, E2F1, and TP53 remains to be clarified. Interestingly, experiments in mouse models have proven that conditional T-cell specific deletion of Cdkn1c gene may induce a differentiation block at the DN3 to DN4 transition, and that the loss of this gene in the absence of Tp53 led to aggressive thymic lymphomas.

          Results

          In this manuscript, we demonstrated that the simultaneous deregulation of CDKN1C, E2F1, and TP53 genes by epigenetic mechanisms and/or the deregulation of specific microRNAs, together with additional impairing of TP53 function by the expression of dominant-negative isoforms are common features in primary human T-LBLs.

          Conclusions

          Previous experimental work in mice revealed that T-cell specific deletion of Cdkn1c accelerates lymphomagenesis in the absence of Tp53. If, as expected, the consequences of the deregulation of the CDKN1C-E2F1-TP53 axis were the same as those experimentally demonstrated in mouse models, the disruption of this axis might be useful to predict tumor aggressiveness, and to provide the basis towards the development of potential therapeutic strategiesin human T-LBL.

          Electronic supplementary material

          The online version of this article (10.1186/s12885-018-4304-y) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database

          MicroRNAs (miRNAs) are small non-coding RNAs of approximately 22 nucleotides, which negatively regulate the gene expression at the post-transcriptional level. This study describes an update of the miRTarBase (http://miRTarBase.mbc.nctu.edu.tw/) that provides information about experimentally validated miRNA-target interactions (MTIs). The latest update of the miRTarBase expanded it to identify systematically Argonaute-miRNA-RNA interactions from 138 crosslinking and immunoprecipitation sequencing (CLIP-seq) data sets that were generated by 21 independent studies. The database contains 4966 articles, 7439 strongly validated MTIs (using reporter assays or western blots) and 348 007 MTIs from CLIP-seq. The number of MTIs in the miRTarBase has increased around 7-fold since the 2014 miRTarBase update. The miRNA and gene expression profiles from The Cancer Genome Atlas (TCGA) are integrated to provide an effective overview of this exponential growth in the miRNA experimental data. These improvements make the miRTarBase one of the more comprehensively annotated, experimentally validated miRNA-target interactions databases and motivate additional miRNA research efforts.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            CDK inhibitors: cell cycle regulators and beyond.

            First identified as cell cycle inhibitors mediating the growth inhibitory cues of upstream signaling pathways, the cyclin-CDK inhibitors of the Cip/Kip family p21Cip1, p27Kip1, and p57Kip2 have emerged as multifaceted proteins with functions beyond cell cycle regulation. In addition to regulating the cell cycle, Cip/Kip proteins play important roles in apoptosis, transcriptional regulation, cell fate determination, cell migration and cytoskeletal dynamics. A complex phosphorylation network modulates Cip/Kip protein functions by altering their subcellular localization, protein-protein interactions, and stability. These functions are essential for the maintenance of normal cell and tissue homeostasis, in processes ranging from embryonic development to tumor suppression.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.

              TP53 gene mutations are one of the most frequent somatic events in cancer. The IARC TP53 Database (http://p53.iarc.fr) is a popular resource that compiles occurrence and phenotype data on TP53 germline and somatic variations linked to human cancer. The deluge of data coming from cancer genomic studies generates new data on TP53 variations and attracts a growing number of database users for the interpretation of TP53 variants. Here, we present the current contents and functionalities of the IARC TP53 Database and perform a systematic analysis of TP53 somatic mutation data extracted from this database and from genomic data repositories. This analysis showed that IARC has more TP53 somatic mutation data than genomic repositories (29,000 vs. 4,000). However, the more complete screening achieved by genomic studies highlighted some overlooked facts about TP53 mutations, such as the presence of a significant number of mutations occurring outside the DNA-binding domain in specific cancer types. We also provide an update on TP53 inherited variants including the ones that should be considered as neutral frequent variations. We thus provide an update of current knowledge on TP53 variations in human cancer as well as inform users on the efficient use of the IARC TP53 Database.
                Bookmark

                Author and article information

                Contributors
                pilar.lopez@cbm.csic.es
                pfernandezn@isciii.es
                cvaquero@cbm.csic.es
                mvilla@cbm.csic.es
                ograna@cnio.es
                macobos@cbm.csic.es
                jllopez@fjd.es
                pllamas@fjd.es
                lgonzalez@cbm.csic.es
                isastre@cbm.csic.es
                mpollan@isciii.es
                mmalumbres@cnio.es
                +34-911964653 , javier.santos@uam.es
                +34-911964653 , jfpiqueras@cbm.csic.es
                Journal
                BMC Cancer
                BMC Cancer
                BMC Cancer
                BioMed Central (London )
                1471-2407
                16 April 2018
                16 April 2018
                2018
                : 18
                : 430
                Affiliations
                [1 ]ISNI 0000 0001 2183 4846, GRID grid.4711.3, Department of Cellular Biology and Immunology, Severo Ochoa Molecular Biology Center (CBMSO), , CSIC-Madrid Autonomous University, ; 28049 Madrid, Spain
                [2 ]GRID grid.419651.e, Institute of Health Research, , Jiménez Díaz Foundation, ; Madrid, Spain
                [3 ]ISNI 0000 0000 9314 1427, GRID grid.413448.e, Consortium for Biomedical Research in Rare Diseases (CIBERER), , Carlos III Institute of Health, ; Madrid, Spain
                [4 ]ISNI 0000 0000 9314 1427, GRID grid.413448.e, Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, , Carlos III Institute of Health, ; Madrid, Spain
                [5 ]Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
                [6 ]ISNI 0000 0000 8700 1153, GRID grid.7719.8, Bioinformatics Unit, Structural Biology and Biocomputing Programme, , Spanish National Cancer Research Center (CNIO), ; Madrid, Spain
                [7 ]ISNI 0000 0000 8700 1153, GRID grid.7719.8, Cell Division and Cancer Group, Molecular Oncology Programme, , Spanish National Cancer Research Centre (CNIO), ; Madrid, Spain
                Author information
                http://orcid.org/0000-0003-4520-6785
                Article
                4304
                10.1186/s12885-018-4304-y
                5902834
                29661169
                4ba2bee1-fbb3-4eec-a3df-c1c5f35ea637
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 26 June 2017
                : 26 March 2018
                Funding
                Funded by: Spanish Ministry of Economy and Competitiveness
                Award ID: SAF2015-70561-R
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2018

                Oncology & Radiotherapy
                t-cell lymphoblastic lymphoma,cdkn1c-e2f1-tp53 deregulation,promoter hypermethylation,deregulation of mirnas

                Comments

                Comment on this article